Evidence map›Paper›PMID 28197070›Full record

ReviewFrontiers in molecular neuroscience2017

Role of APP Interactions with Heterotrimeric G Proteins: Physiological Functions and Pathological Consequences.

Philip F Copenhaver, Donat Kögel

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in molecular neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. CB1R activates the epilepsy-associated protein Go to regulate neurotransmitter release and synaptic plasticity in the cerebellum.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. 1-L Transcription in Alzheimer's Disease.Current issues in molecular biology · 2022
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Going Too Far Is the Same as Falling ShortFrontiers in cellular neuroscience · 2019
    Review
  16. Article
  17. Article
  18. The Role of APP in Structural Spine Plasticity.Frontiers in molecular neuroscience · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Philip F CopenhaverDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Sciences University, Portland OR, USA.
Donat KögelExperimental Neurosurgery, Goethe University Frankfurt Frankfurt am Main, Germany.
Goethe University Frankfurt · DEOregon Health & Science University · US

Funding

ROLE OF APP-RELATED PROTEINS DURING NEURONAL MIGRATIONR01AG025525 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI COPENHAVER, PHILIP F · 2006 to 2010
$1.4M
Macrophage-dependent regulation of neurotoxic APP fragments in a model systemR21NS078363 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI COPENHAVER, PHILIP F · 2014 to 2015
$424k
Role of APP-related Proteins During Neuronal MigrationR56AG025525 · NIA · OREGON HEALTH AND SCIENCE UNIVERSITY · PI COPENHAVER, PHILIP F · 2005 to 2005
$153k
NIA NIH HHS R01 AG025525NIA NIH HHS R56 AG025525NINDS NIH HHS R21 NS078363
6 · The paper itself

Abstract

Following the discovery that the amyloid precursor protein (APP) is the source of β-amyloid peptides (Aβ) that accumulate in Alzheimer's disease (AD), structural analyses suggested that the holoprotein resembles a transmembrane receptor. Initial studies using reconstituted membranes demonstrated that APP can directly interact with the heterotrimeric G protein Gαo (but not other G proteins) via an evolutionarily G protein-binding motif in its cytoplasmic domain. Subsequent investigations in cell culture showed that antibodies against the extracellular domain of APP could stimulate Gαo activity, presumably mimicking endogenous APP ligands. In addition, chronically activating wild type APP or overexpressing mutant APP isoforms linked with familial AD could provoke Go-dependent neurotoxic responses, while biochemical assays using human brain samples suggested that the endogenous APP-Go interactions are perturbed in AD patients. More recently, several G protein-dependent pathways have been implicated in the physiological roles of APP, coupled with evidence that APP interacts both physically and functionally with Gαo in a variety of contexts. Work in insect models has demonstrated that the APP ortholog APPL directly interacts with Gαo in motile neurons, whereby APPL-Gαo signaling regulates the response of migratory neurons to ligands encountered in the developing nervous system. Concurrent studies using cultured mammalian neurons and organotypic hippocampal slice preparations have shown that APP signaling transduces the neuroprotective effects of soluble sAPPα fragments via modulation of the PI3K/Akt pathway, providing a mechanism for integrating the stress and survival responses regulated by APP. Notably, this effect was also inhibited by pertussis toxin, indicating an essential role for Gαo/i proteins. Unexpectedly, C-terminal fragments (CTFs) derived from APP have also been found to interact with Gαs, whereby CTF-Gαs signaling can promote neurite outgrowth via adenylyl cyclase/PKA-dependent pathways. These reports offer the intriguing perspective that G protein switching might modulate APP-dependent responses in a context-dependent manner. In this review, we provide an up-to-date perspective on the model that APP plays a variety of roles as an atypical G protein-coupled receptor in both the developing and adult nervous system, and we discuss the hypothesis that disruption of these normal functions might contribute to the progressive neuropathologies that typify AD.

Indexed as

Alzheimer’s diseaseamyloid precursor proteinAPPLDrosophilaGαoManducamigrationstress signaling

Identifiers

PMID28197070
PMCPMC5281615
OpenAlexW2580024777

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.